Rising Costs and Access Challenges in Weight Loss Medications
TL;DR
Employers like HCA Healthcare are dropping coverage for weight loss drugs such as Zepbound and Wegovy due to rising costs and are directing employees to manufacturer discount programs, which may be cheaper than insurance coverage. The growth of direct-to-consumer programs by pharma companies Eli Lilly and Novo Nordisk is contributing to this shift, potentially making these drugs less affordable for the general public despite expanding access.
- Employers drop coverage for weight loss drugs as pharma’s direct-to-consumer programs grow statnews.com
- Opinion | How to cut the velvet rope to GLP-1s The Washington Post
- Obesity recognition ‘going in right direction’ amid GLP-1 revolution, but obstacles remain thehill.com
- HR Leaders Address Rising Costs of GLP-1 Medications and Gene Therapies with Value-Based Care Strategies geneonline.com
- Covering the High Cost of Weight Loss Drugs National Conference of State Legislatures (NCSL)
Want the full story? Read the original reporting
Read on statnews.com